Viz.ai
AI stroke detection deployed across 1,400+ US/EU hospitals, FDA-cleared and Medicare-reimbursed for neurology care
Overview
Viz.ai is an AI triage and routing platform for neurovascular care deployed in 1,400+ hospitals covering 220 million patients across North America and Europe. Its flagship module detects Large Vessel Occlusions (LVO) in CT imaging and sends immediate alerts to thrombectomy teams to accelerate treatment. Viz holds multiple FDA 510(k) clearances for ischemic stroke, intracranial hemorrhage, and pulmonary embolism, and is reimbursed by Medicare. Peer-reviewed research proves 30-60 minute reductions in door-to-puncture times for stroke cases via Viz. The upside: clear ROI in reducing stroke mortality and disability.
Viz.ai does not offer a French-language interface. Pricing is not public: cost depends on hospital size and active module count (stroke LVO, ICH, PE, aortic disease), with multi-year contracts negotiated per establishment. An API enables deep integration to existing HIS systems. The main barrier for a small European structure is the absence of localization, but also that Viz, while FDA-cleared, lacks formal regulatory approval outside the US: use in regulated healthcare settings outside the US may fall outside legal frameworks without specific clearance.
Our verdict
Best for academic and regional mid-to-large hospitals treating hundreds of strokes annually and accepting multi-year Viz engagement: clear ROI on reducing stroke morbidity. Not for you if you run a small private clinic or operate in a regulated region without clarity: the absence of localization and transparent pricing, plus uncertain regulatory status outside the US, makes Viz.ai enterprise-only.